Interventional cardiologists at The Mount Sinai Hospital in October became the first in the world to use a new device to remove hard calcium buildup in a coronary artery in preparation for the placement of a stent to improve blood flow through the artery. The device, the Diamondback 360® Coronary Orbital Atherectomy System, was approved by the U.S. Food and Drug Administration one day before it was brought to Mount Sinai for use.
Since then, Mount Sinai’s cardiac catheterization team has performed more than 25 procedures under the leadership of Samin K. Sharma, MD, Director of Clinical and Interventional Cardiology at The Mount Sinai Hospital. Dr. Sharma says there have been no complications during or after the procedures.
Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief at The Mount Sinai Medical Center, has been selected as the next Editor-in-Chief of the Journal of the American College of Cardiology (JACC), the world’s most widely read cardiovascular journal. His five-year term will begin in July 2014.
JACC is the flagship publication of the American College of Cardiology (ACC), a 43,000-member organization dedicated to improving cardiovascular care and heart health around the world through education, research, and advocacy.
Valentin Fuster, MD, PhD, Director of Mount Sinai Heart, presented landmark research on diabetes and heart disease at the American Heart Association (AHA) Scientific Sessions 2012. During the conference, the AHA also honored Dr. Fuster with its 2012 Research Achievement Award for his many significant contributions to cardiovascular medicine.
“With a laser-like focus on translational research, Dr. Fuster has added greatly to our understanding of the pathogenesis of coronary artery disease and thrombosis,” says AHA President Donna Arnett, PhD, MSPH. “Among his laboratory’s provocative advancements in medical science are numerous ‘firsts,’ including the original understanding of the role of platelets in heart disease and the revelation that plaque composition plays a crucial role in propensity for a heart lesion to rupture.”
When Daquain Jenkins, 29, left The Mount Sinai Hospital last year, he became the first patient in the New York metropolitan area to return home to await a heart transplant with the assistance of a portable artificial heart.
The milestone was remarkable in a number of ways. First, the Total Artificial Heart, manufactured by SynCardia Systems, Inc., in Tucson, Arizona, replaces both failing heart ventricles and four heart valves, eliminating end-stage biventricular failure. It is immediately available to patients, and serves as a bridge while they await a suitable heart donor. In addition, it allows patients to move freely and manage everyday chores while wearing a backpack that stores the 13.5-pound battery-driven device.